DiaMedica Therapeutics Inc (DMAC) is a Healthcare · Biotechnology company listed on NASDAQ. Price $6.90 (+0.73%), Market cap $0.30B, 52-week low–high $3.51 ~ $9.39.
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment of inflammatory diseases, such as acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics
Financial statements, price targets, institutional (13F) holdings and related news for DiaMedica Therapeutics Inc are updated in real time on BlackAll Trade.
DiaMedica Therapeutics Inc trades at $6.90 (+0.73%). Real-time quotes and charts are available on BlackAll Trade.
DiaMedica Therapeutics Inc has a market cap of about $0.30B.
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutical